What is it and what does it include?
The primary objective of the original study was to assess the safety of semagacestat in Alzheimer's disease (AD) patients during 24 months of open-label treatment. Baseline for the efficacy measures is defined as the baseline for feeder studies LFAN (NCT00594568) and LFBC (NCT00762411). For all safety analyses (adverse events), baseline for patients will be week 0 of this study (LFBF). Preliminary results from LFAN and LFBC showed Semagacestat did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living.
How can I use this dataset to advance my research?
This dataset is ideal if:
- you’re studying the profile of γ-secretase inhibitors, compounds that inhibit γ-secretase, the pivotal enzyme that generates Aβ, and that have reached the clinic.
Has this dataset helped researchers understand Alzheimer’s and other dementias better?
Of course!
- AD & Drug development:
In 2009, results showed Semagacestat treatment lowers plasma, cerebrospinal fluid and brain Aβ in a dose-dependent manner in animals and plasma and cerebrospinal fluid Aβ in humans, compared with placebo-treated patients. June 2009 – DOI: https://doi.org/10.1517/14656560903044982
- AD & Clinical trials:
In 2010, trials showed Y-secretase inhibitors may cause intestinal goblet cell hyperplasia, thymus atrophy, decrease in lymphocytes, and alterations in hair color, effects associated with the inhibition of the cleavage of Notch, a protein involved in cell development and differentiation. Nevertheless, at least other two promising γ-secretase inhibitors are being tested clinically. This class of drugs represents a major hope to slow the rate of decline of AD. June 2010 – DOI: https://doi.org/10.1111/j.1755-5949.2010.00164.x